E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Counteracting Drug Resistant Mechanisms in Cancer"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".

Deadline for manuscript submissions: 15 January 2018

Special Issue Editor

Guest Editor
Prof. Dr. M. Helena Vasconcelos

FFUP – Faculdade de Farmácia da Universidade do Porto, Porto 4050-313, Potugal; I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto 4200-135, Portugal
Website | E-Mail
Interests: cancer drug resistance; cancer multidrug resistance; intercellular transfer of drug resistance mediated by Extracellular Vesicles (EVs); new approaches to overcome drug resistance; drug-efflux pumps; escape from apoptosis; autophagy; metabolic alterations associated with drug resistance; tumour-microenvironment interactions; cancer stem cells; microRNAs; biomarkers of minimal residual disease and of drug resistance

Special Issue Information

Dear Colleagues,

Drug resistance is a major obstacle to the successful treatment of cancer patients. The intratumor genetic heterogeneity and tumor dynamics, together with the presence of cancer stem cells, make it a very difficult problem to overcome. This Special Issue of Molecules aims to collect review and research articles on novel approaches for counteracting drug resistant mechanisms in cancer. Topics may include: i) novel compounds or small molecules designed to inhibit targets known to be responsible for chemoresistance (e.g. drug-efflux pumps or antiapoptotic proteins), ii) natural compounds that circumvent drug resistance, iii) molecules that target cancer stem cells, iv) antimiRs or siRNAs designed to inhibit targets responsible for chemoresistance, or v) drug delivery approaches to improve drug response.

Prof. Dr. M. Helena Vasconcelos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • drug resistance
  • multidrug resistance
  • chemoresistance
  • chemosensitisation
  • drug-efflux pumps
  • ATP-binding cassette (ABC) transporters
  • cell death
  • apoptosis; autophagy
  • p53
  • mutations
  • DNA repair
  • tumour-microenvironment interactions
  • EMT
  • cancer stem cells
  • natural products
  • small molecules
  • siRNAs
  • microRNAs
  • antimiRs
  • drug delivery
  • nanotechnology
  • liposomes
  • extracellular vesicles

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines
Molecules 2017, 22(10), 1717; doi:10.3390/molecules22101717
Received: 19 September 2017 / Revised: 29 September 2017 / Accepted: 6 October 2017 / Published: 13 October 2017
PDF Full-text (3059 KB) | HTML Full-text | XML Full-text
Abstract
Low efficiency of chemotherapy in ovarian cancer results from the development of drug resistance. Cisplatin (CIS) and topotecan (TOP) are drugs used in chemotherapy of this cancer. We analyzed the development of CIS and TOP resistance in ovarian cancer cell lines. Incubation of
[...] Read more.
Low efficiency of chemotherapy in ovarian cancer results from the development of drug resistance. Cisplatin (CIS) and topotecan (TOP) are drugs used in chemotherapy of this cancer. We analyzed the development of CIS and TOP resistance in ovarian cancer cell lines. Incubation of drug sensitive cell lines (W1 and A2780) with cytostatic drugs was used to determine the primary response to CIS and TOP. Quantitative polymerase chain reaction (Q-PCR) was performed to measure the expression levels of the genes. We observed decreased expression of the MCTP1 gene in all resistant cell lines. We observed overexpression of the S100A3 and HERC5 genes in TOP-resistant cell lines. Increased expression of the S100A3 gene was also observed in CIS-resistant A2780 sublines. Overexpression of the C4orf18 gene was observed in CIS- and TOP-resistant A2780 sublines. A short time of exposure to CIS led to increased expression of the ABCC2 gene in the W1 and A2780 cell lines and increased expression of the C4orf18 gene in the A2780 cell line. A short time of exposure to TOP led to increased expression of the S100A3 and HERC5 genes in both sensitive cell lines, increased expression of the C4orf18 gene in the A2780 cell line and downregulation of the MCTP1 gene in the W1 cell line. Our results suggest that changes in expression of the MCTP1, S100A3 and C4orf18 genes may be related to both CIS and TOP resistance. Increased expression of the HERC5 gene seems to be important only in TOP resistance. Full article
(This article belongs to the Special Issue Counteracting Drug Resistant Mechanisms in Cancer)
Figures

Figure 1a

Back to Top